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Wednesday, February 11, 2015 585asodium currents in a wide range of more common acquired disorders that are
linked by disease-altered INaL, including ischemic heart disease and heart fail-
ure. While preferential pharmacological block of INaL by several Na
þ-channel
blocking drugs has proven to be an important and useful clinical approach to
manage LQT-3 arrhythmias, we still lack a fundamental understanding of the
pharmacological determinants of this selectivity. We have previously identified
a novel lethal LQT3 variant, F1473C, which displays slowed inactivation,
altered channel availability, and a significant INaL. Here we report for the first
time single channel recordings from F1473C channels and find that late reopen-
ing events during prolonged depolarizations underlie pathological INaL for this
mutation. To further unravel the mechanism of action of of Ranolazine, a drug
known to preferentially block INaL, we studied its effects on single F1473C
channels. Ranolazine reduced the number of late reopening events in a manner
consistent with block of whole cell currents. These experiments represent the
first exploration of the block of INaL caused by late reopening, and present a
framework for further studies of the mechanisms of drug block in these
channels.
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Recent progress in the field of embryonic and induced pluripotent stem cell
(iPSC)-derived cardiomyocytes led to flourishing of a variety of pharma-
cology and drug safety screening assays, relying on diverse principles,
such as optical measurements using wide dynamic range Ca2þ-sensitive or
transmembrane voltage-sensitive dyes, or multi-electrode arrays allowing
field potential measurements, action potential (AP) conduction velocity and
2D local activation mapping, and impedance changes in cultured monolayers.
In view of new recommendations of the cardiac in vitro pro-arrhythmia
(CiPA) consortium of multiple ion channel pharmacology assessment
(MICE), combined with AP and electrophysiology model-based testing of
arrhythmia-prone conditions, we developed a complex automated patch-
clamp assay, combining current-clamp and voltage-clamp protocols, appli-
cable to commercial high-purity human iPSC-derived cardiomyocyte prepa-
rations, e.g. iCell Cardiomyocytes or Cor.4U cardiomyocytes with the
CytoPatch 2 equipment. To study stimulus-triggered APs we suppressed
spontaneous firing via continuous injection of a faint hyperpolarizing current
(10 or 20 pA), and for removal of fast oscillations during rapid AP up-
stroke we applied a 60 Hz Gaussian filter implemented in Clampfit10. APs
were analyzed for automated measurement of resting and peak potential,
maximum phase 0 slope (dV/dtmax), and various AP durations: APD10,
APD50, APD90. Nifedipine elicited pacing frequency-dependent reductions
in APD50 (16.1% and 12.0% of control values at 1 and 10 mM, respectively),
cisapride 0.1 mM prolonged APD90 to 176.2%, and TTX 10 mM decreased
dV/dtmax to 33.3% and APD90 to 80.4% of control values. Voltage-clamp
measurements evidenced a progressive increase from 10 to 15 days in vitro
(d.i.v.) for densities (pA/pF, mean5SD) of peak Naþ current (119.6567.3 to
406.75799.2), L-type Ca2þ current (2.7452.84 to 3.4354.05), plateau cur-
rent within a 2-s depolarizing pulse at þ40 mV (1.2851.42 to 3.1654.68),
while transient outward current was more steady (0.7751.14, 10 d.i.v. and
0.6150.75,14 d.i.v.).
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Glutamate NMDA receptors are increasingly employed in drug discovery for
numerous clinical indications. Multiple receptor isoforms with distinct brain
distributions and properties arise by selective splicing of the NR1 transcripts
and differential expression of NR2 (A-D) subunit subtypes of NMDA recep-
tors. NR1/NR2A and NR1/NR2B represent the most abundant subtypes.
Recent advances in electrophysiology-based HTS assays however, demand
renewed characterization of these receptors on automated patch clamp plat-
forms. In this study we used IonWorks Barracuda, an HTS platform that
can operate in 384-well format, population patch clamp (PPC) mode. Side-
by-side comparisons of pharmacological properties of NR1/NR2A and
NR1/NR2B glutamate receptor responses to L-glutamate and NMDA, phar-
macological profiling and comparison of eight competitive and uncompetitiveinhibitors and comparison of kinetic of responses were obtained in ‘‘single
hole’’ (SH) and PPC modes. Experiment protocols were developed to
routinely produce signals ~2 nA and ~1 nA for NR1/NR2A and NR1/
NR2B, respectively, in PPC mode. Under our experimental procedures both
NR1/N2A and NR1/NR2B showed good uniformity with Z’ factor > 0.6.
We found that EC50 concentrations for L-glutamate were 3.8 mM and
2.0 mM for NR1/NR2A and NR1/NR2B, respectively. NMDA appeared to
be a less potent partial agonist at NR1/NR2B (>75% and EC50¼18-
20 mM), whereas NMDA appeared to be a full agonist at NR1/NR2A with
EC50 ¼ 100 mM. These EC50 values were consistent with literature data
obtained with conventional manual patch clamp methods. Additionally, we
confirmed selectivity of the uncompetitive inhibitor, ifenprodil, towards
NR1/NR2B receptors with IC50Ifen¼ 19.3 mM, whereas NR1/NR2A recep-
tors were unaffected. Potential variability in IC50 values of uncompetitive
inhibitors due to open-pore dependence will be discussed. Our data demon-
strate the potential of a robust HTS patch clamp assay for profiling new
chemical entities against NMDA receptor subtypes.
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Cystic Fibrosis (CF) is a genetically-inherited disease characterized by the
loss of function of the Cystic Fibrosis Transmembrane Conductance Regu-
lator (CFTR), a chloride ion channel located in the epithelial lining of
the lungs and pancreas. CFTR function is reduced or eliminated as the
result of a variety of genetic mutations, leading to harmful fluid buildup,
decreased organ function, and eventually death. Our goal is to identify and
characterize the molecular interactions of several disease-relevant mutations
of CFTR with a variety of small molecule modulators of the protein. To
this end, we use a highly-sensitive label-free detection method based on
backscattering interferometry (BSI). By displaying CFTR in a native mem-
brane environment, we have observed and characterized the interactions
of several small molecule modulators, obtaining both binding affinities and
structural information about CFTR. This information has allowed us to
conclusively determine the previously unknown binding site for one of these
modulators.
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Dantrolene is a muscle relaxant that has been used clinically as the treatment
for malignant hyperthermia. Dantrolene acts on skeletal and cardiac muscle
by inhibiting Ca2þ release from the SR. However, single channel studies fail
to see any effect of dantrolene on RyRs. Calmodulin (CaM) regulates RyR2
directly by binding to RyR2 and dantrolene influences CaM binding to
RyR2. CaM can dissociate from RyR2 within ~1 min so when RyR2 are iso-
lated form cells and examined in artificial lipid bilayers, CaM is not usually pre-
sent. Thus, we hypothesized that CaM is the missing protein required for
dantrolene inhibition of RyR2.
Single channel recordings were obtained from RyR2 isolated from sheep
heart and incorporated into artificial lipid bilayers. Control RyR2 activity
was measured for periods of 1 min, and then during 1 min exposure to
dantrolene and then again after washout. This was repeated in the absence
and presence of exogenous 100 nM CaM. In diastolic cytoplasmic [Ca2þ]
(100 nM), dantrolene (50 mM) reduced the mean open probability of RyR2
to 45 5 6 % in the presence of CaM (n ¼ 7, p < 0.05, student paired
t-test) but had no significant effect when CaM was absent (95 5 9 %,
n¼20, p ¼ 0.24). Dantrolene exhibited a hyperbolic dose-response in the
presence of CaM with an IC50 of 0.165 0.03 mM and with a saturating rela-
tive Po (Emax) of 52 5 4 %. Emax increased to one as cytoplasmic Ca
2þ was
increased to levels above 1 mM.
In saponin permeablized mouse cardiomyocytes supplemented with 100 nM
CaM, dantrolene reduced the frequency and amplitude of Ca2þ waves
with an IC50 of 0.3 mM. However, when cells were depleted of CaM,
dantrolene had no effect. Thus CaM is essential for inhibitory action of
dantrolene.
